An evolving library of
covalent small molecules.
Selective small molecules for cancer and immune disorders.
We are leveraging our proprietary chemoproteomic platform to advance a deep and diversified pipeline of highly selective small molecule therapeutics targeting high value, traditionally undruggable targets in oncology and immunology. Our lead programs target NRF2, STAT3 and WRN.
Target
Indication
Discovery
Preclinical Validation
Lead Optimization
IND Enabling
Phase 1
Phase 2/3
Rights
NRF2 Mutant Cancers
IBD
Immunology
Oncology
Oncology
Oncology & Immunology
Oncology & Immunology
Oncology & Immunology
Vividion is also advancing a number of undisclosed programs that are in the lead optimization phase.
Publications
We’re hiring! Come work with a passionate team, pushing the boundaries of what small molecules are capable of.
